You searched for "IFIS"
The International Council of Ophthalmology: what is it and is it useful for UK ophthalmologists?
1 April 2018
| Simon Keightley
|
EYE - General
ICO Director for Examinations and Assessments, Simon Keightley, explains the history and role of the organisation today, as well as outlining recent changes to the ICO examinations. The International Council of Ophthalmology (ICO) is the only international medical specialty organisation...
The results of the last survey Feb 2020
I appreciate that I keep on reiterating it, but again we see so much practice variance. Who is right and who is wrong? Is there a right or wrong approach? And does it matter? I think it probably does matter....Embryology in clinical practice
1 February 2016
| Naser Ali
|
EYE - Cataract, EYE - Cornea, EYE - General, EYE - Glaucoma, EYE - Imaging, EYE - Neuro-ophthalmology, EYE - Oculoplastic, EYE - Oncology, EYE - Orbit, EYE - Paediatrics, EYE - Pathology, EYE - Refractive, EYE - Strabismus, EYE - Vitreo-Retinal
The fascinating world of embryology is both beautiful and practical. It is a home video of our evolutionary history through the ages from the single cell through to the life aquatic, the development of gut, limbs and brain, and most...
Principles of management
Whatever section of pathology is to blame and wherever it strikes, the aim of treatment is always the same. Find the cause if you can. Establish the effects of the cause. Halt the pathological process if you can. Reverse its...A case of ‘60-day glaucoma’
3 April 2023
| Jagruti Godhaniya, Rajan Paul
|
EYE - General
Neovascular glaucoma (NVG) has been called ‘90-’ or ‘100-day glaucoma’ in the past due to its typical development three months after the onset of central retinal vein occlusion (CRVO). In reality, NVG can occur anywhere between two weeks and two...
Midland Eye performs its first Presserflo Microshunt to treat Glaucoma
Eye clinic, Midland Eye, announces the success of its first sight-saving Preserflo Microshunt glaucoma procedure.
One-year result of XEN45 implant for glaucoma: efficacy, safety, and postoperative management
1 August 2018
| Sofia Rokerya
|
Glaucoma
The authors report a retrospective, non-randomised interventional case series of 39 patients who underwent a standalone XEN45 implantation. All 39 patients (female: male=1.2: 1) completed 12-month follow-up. Mean age was 70.1 years (range 32–92). Primary outcome measures were the intraocular...
DISC lens slow myopia progression in Hong Kong Chinese schoolchildren
1 April 2014
| Jonathan Chan
|
Ophthalmology, Paediatric Ophthalmology / Strabismus
|
Child Health (Paediatrics), Clinical Trial, Contact Lens, Optics and Refraction
This is a prospective double-blind randomised trial between September 2007 and October 2009. It included 221 children aged 8-13 years, with myopia between -1 and -5 Dioptres ≤1.00D. There were 111 patients in the defocus incorporated soft contact DISC group...
The bionic eye – behind the headlines
Multiple visual prosthetic projects and other vision regeneration initiatives being tested in preclinical and clinical development worldwide illustrate continuing progress and opportunities in addressing profound blindness from hereditary retinal diseases and other causes (Table 1). Three implantable bionic vision systems...
Practice patterns of uveal melanoma management with Iodine-125 brachytherapy
5 August 2020
| Annes Ahmeidat
|
EYE - Pathology, EYE - Oncology
|
Brachytherapy, Treatment practices, Uveal melanoma
With the 2006 Collaborative Ocular Melanoma Study Group (COMS) study demonstrating no difference in survival outcomes for participants randomised to either iodine-125 brachytherapy or enucleation, the majority of primary uveal melanomas in the United States are now treated with brachytherapy....
The eye without tears
1 June 2016
| Hector Bryson Chawla
|
EYE - General
The Art is long and Life is short. So goes the dispiriting tag in Latin and flung from day one and at regular intervals thereafter at idle medical students who, inevitably brainwashed, come by graduation to believe that the only...
